<DOC>
	<DOCNO>NCT01097655</DOCNO>
	<brief_summary>Usage , dose , tolerability , effectiveness Kaletra tablet Human Immunodeficiency Virus-infected patient .</brief_summary>
	<brief_title>Study Usage , Dosing , Tolerability , Effectiveness Kaletra Tablet</brief_title>
	<detailed_description>The objective study observe collect data usage , dose , tolerability , effectiveness Kaletra tablet . In patient study show impact change therapy Kaletra tablet regimens tolerability .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Patients Human Immunodeficiency Virus infection Patients treat KALETRA tablet , independent participation study Hypersensitivity Kaletra ingredient Severe liver insufficiency No concommitant astemizole , terfenadine , oral midazolam , triazolam , cisapride , pimozide , amiodarone , ergotamine , dihydroergotamine , ergometrine , methylergometrine , vardenafil St. John 's wort Patients receive 1 protease inhibitor therapy history exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Tolerability</keyword>
	<keyword>Viral load</keyword>
	<keyword>Human immunodeficiency Virus</keyword>
	<keyword>Effectiveness</keyword>
	<keyword>Treatment-na√Øve</keyword>
	<keyword>Tablets</keyword>
	<keyword>Infection</keyword>
	<keyword>Non Nucleoside Reverse Transcriptase Inhibitor</keyword>
</DOC>